{"database":"MetabolomicsWorkbench","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["http://www.metabolomicsworkbench.org/rest/study/study_id/ST001014/mwtab"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Metabolomics"],"technology_type":["Mass Spectrometry","ESI"],"disease":["Cachexia","Cancer"],"species":["Homo Sapiens"],"full_dataset_link":["http://www.metabolomicsworkbench.org/data/DRCCMetadata.php?Mode=Study&StudyID=ST001014"],"study_factor":["Grouping:Weight Stable | Gender:Male","Grouping:Control | Gender:Male","Grouping:Weight Losing | Gender:Male","Grouping:Control | Gender:Female","Grouping:Weight Losing | Gender:Female","Grouping:Weight Stable | Gender:Female"],"tissue":["Blood"],"submitter_affiliation":["Mayo Clinic"],"sample_protocol":["Reversed phase POSITIVE ION MODE."],"repository":["MetabolomicsWorkbench"],"metabolite_name":["S1P","SPA","C18:1-cer","C16-cer","C24:1-cer","C18-cer","C8-cer","C14-cer","Sph","C20-cer","C22-cer","C24-cer"],"data_protocol":[""],"name_synonyms":["sphingolipids, Muscle wasting, primary cancer, Lysosphingolipids, Malignant Neoplasm, Neurogenic muscular atrophy, Malignancy, Blood, Neoplasms, Benign Neoplasm, Muscle hypotrophy, Neurogenic muscle atrophy, Benign Neoplasms, Cancers, Blood Serum, Serum, Tumor, Malignant, Amyotrophy involving the extremities, malignant tumor, wasting - muscle, Malignant Neoplasms, Neoplasias, Muscle atrophy, especially in the lower limbs, Muscle degeneration, Amyotrophy, MT, Benign, Sphingolipid, malignant neoplasm, neurogenic, amyotrophia, Muscular atrophy, muscle wasting, Neoplasm, Malignancies, Wasting syndrome., Serums, Neoplasia, Cancer, Tumors"],"sample_synonyms":["backward, reversed."],"additional_accession":[]},"is_claimable":false,"name":"Sphingolipid Concentrations in Serum for Muscle Wasting in Cancer Cachexia (part-IX)","description":null,"dates":{"publication":""},"accession":"ST001014","cross_references":{"TAXONOMY":["9606"]}}